A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc.
Shanghai JMT-Bio Inc.
Incyte Corporation
CatalYm GmbH
MacroGenics
Hoffmann-La Roche
Mirati Therapeutics Inc.
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Eli Lilly and Company
Gilead Sciences
BioNTech SE
Jazz Pharmaceuticals
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Nanjing Leads Biolabs Co.,Ltd
Shanghai Miracogen Inc.
Bristol-Myers Squibb
STCube, Inc.
ImmunityBio, Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
BeOne Medicines
Genentech, Inc.
Merck Sharp & Dohme LLC
Gilead Sciences
Gilead Sciences
Merck Sharp & Dohme LLC
Sichuan Baili Pharmaceutical Co., Ltd.
Genelux Corporation
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
AbbVie
Sichuan Baili Pharmaceutical Co., Ltd.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Xencor, Inc.
GlaxoSmithKline
BeiGene
Relmada Therapeutics, Inc.
Bristol-Myers Squibb
Gilead Sciences
Alethia Biotherapeutics
Shanghai JMT-Bio Inc.
Akeso
NeoTX Therapeutics Ltd.
ImmunityBio, Inc.
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Novartis
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Pierre Fabre Medicament
Modra Pharmaceuticals